Robert E. Waltermire - 28 Feb 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role: Senior VP, Chief Pharma Dev.
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol: MDGL
Transactions as of: 28 Feb 2025
Net transactions value: -$418,488
Form type: 4
Filing time: 04 Mar 2025, 21:24:28 UTC
Previous filing: 27 Jan 2025
Next filing: 07 Mar 2025
SEC: View on sec.gov

Quoteable Key Fact

"Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 04 Mar 2025."

Quick Takeaways

This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
2 reported transactions and 0 derivative rows are listed below.
Filing timestamp: 04 Mar 2025, 21:24.

What Changed

Previous filing in this sequence was filed on 27 Jan 2025.
Current net transaction value: -$418,488.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MDGL	Common Stock	Sale	$358,717	-1,052	-21%	$340.99	3,903	28 Feb 2025	Direct	F1
transaction	MDGL	Common Stock	Sale	$59,771	-175	-4.5%	$341.55	3,728	28 Feb 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.495 to $341.415, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.52 to $341.57, inclusive.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.495 to $341.415, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $341.52 to $341.57, inclusive.